Genetic risk factors associated with the prognosis of myocardial infarction in young patients

Thrombosis and Haemostasis

Volumn 88, Issue 4, 2002, Pages 694-697

  Li, Yi Heng ^a   Chen, Jyh Hong ^a   Guo, How Ran ^a   Tsai, Wei Chuan ^a   Chao, Ting Hsing ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 7; DNA; DNA FRAGMENT; GLYCOPROTEIN IIIA; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN;

ACUTE HEART INFARCTION; ADULT; ALLELE; ANGINA PECTORIS; ASIAN; CAUCASIAN; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DNA EXTRACTION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; HEART DEATH; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVASCULARIZATION; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL; TEACHING HOSPITAL; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HEART INFARCTION; MIDDLE AGED; TOPOGRAPHY;

ADULT; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TOPOGRAPHY, MEDICAL;

EID: 0036799422     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613282     Document Type: Letter

References (21)

1. DeWood MA, Spores J, Notske RN. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
2. Anderson JL, King GJ, Bair TL, et al. Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction and coronary artery disease. J Am Coll Cardiol 1999; 33: 727-733.
3. Margaglione M, Grandone E, Cappucci G, et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997; 77: 605. .
4. Green F, Kelleher C, Wilkes H, et al. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-6.
5. Li YH, Chen JH, Tsai WC, et al. Synergistic effect of thrombomodulin promoter -33G/A polymorphism and smoking on the onset of acute myocardial infarction. Thromb Haemost 2002; 87: 86-91.
6. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
7. Wang LX, Sim AS, Badenho RF, et al. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996; 2: 41-5.
8. Tanaka S, Ohnoki S, Shibata H, et al. Gene frequencies of human platelet antigens on glycoprotein IIIa in Japanese. Transfusion 1996; 36: 813-7.
9. Hato T, Minamoto Y, Fukuyama T, et al. Polymorphisms of HPA-1 through 6 on platelet membrane glycoprotein receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am J Cardiol 1997; 80: 1222-4.
10. Herrmann SM, Poirier O, Marques-Vidal P, et al. The Leu33/Pro polymorphism (P1A1/P1A2) of the glycoprotein IIIa (GP IIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb Haemost 1997; 77: 1179-81.
11. Ridker PM, Hennekens CH, Schmitz C, et al. P1A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis. Lancet 1997; 349: 385-8.
12. Ardissino D, Mannucci PM, Merlini PA, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46-51.
13. Iwai N, Shimoike H, Nakamura Y, et al. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 1998; 136: 109-14.
14. Song J, Yoon YM, Jung HJ, et al. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353 → Gln polymorphism in Korean patients with coronary artery disease. J Koren Med Sci 2000; 15: 146-52.
15. Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-41.
16. Ridker PM, Hennekens CH, Lindpaintner K, et al. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62.
17. Tamaki S, Iwai N, Nakamura Y, et al. Variation of the factor VII gene and ischemic heart disease in Japanese subjects. Coronary Artery Disease 1999; 10: 601-6.
18. Lane A, Green F, Scarabin PY, et al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indication of MI risk in ECTIM study. Atherosclerosis 1996; 119: 119-27.
19. Doggen CJM, Manger Cats V, Bertina RM, et al. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998; 80: 281-5.
20. Ireland H, Kunz G, Kyriakoulis K, et al. Thrombomodulin gene mutations associated with myocardial infarction. Circulation 1997; 96: 15-8.
21. Le Flem L, Picard V, Emmerich J, et al. Mutations in promoter region of thrombomodulin and venous thromboembolic disease. Arterioscler Thromb Vasc Biol 1999; 19: 1098-104.